Simulations Plus Inc(SLP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 46.22 | EPS (ttm) | 0.4 | Insider Own | 0.23% | Shs Outstand | 20.2M | Perf Week | - |
| Market Cap | 0.37B | Forward P/E | - | EPS next Y | - | Insider Trans | -51.09% | Shs Float | 20.2M | Perf Month | 0.33% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | - | Inst Own | 88.71% | Short Float | 14.27% | Perf Quarter | 1.59% |
| Income | 0.01B | P/S | 4.56 | EPS this Y | - | Inst Trans | - | Short Ratio | 9.7 | Perf Half Y | 28.74% |
| Sales | 0.08B | P/B | 2.69 | EPS next 5Y | - | ROA | 5.64% | Short Interest | 2.88M | Perf YTD | 1.48% |
| Book/sh | 6.88 | P/C | 7.48 | EPS past 3/5Y | - | ROE | 6.17% | 52W High | -11.95% ($21.01) | Perf Year | 15.48% |
| Cash/sh | 2.47 | P/FCF | 15.24 | Sales past 3/5Y | 13.67% 13.74% | ROIC | 5.81% | 52W Low | 66.82% ($11.09) | Perf 3Y | -55.55% |
| Dividend Est. | - | EV/EBITDA | 18.23 | EPS Y/Y TTM | 112.78% | Gross Margin | 62.4% | Volatility(W/M) | 0.15% 0.14% | Perf 5Y | -53.35% |
| Dividend TTM | - | EV/Sales | 3.96 | Sales Y/Y TTM | 2.08% | Oper. Margin | 14.63% | ATR (14) | 0.04 | Perf 10Y | 114.12% |
| Dividend Ex-Date | 2024/7/29 | Quick Ratio | 5.54 | EPS Q/Q | 105.28% | Profit Margin | 9.88% | RSI (14) | 65.07 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.54 | Sales Q/Q | 7.48% | SMA20 | 0.3% ($18.44) | Beta | 1.21 | Target Price | $16 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/7/9 | SMA50 | 0.58% ($18.39) | Rel Volume | 0 | Prev Close | $18.5 |
| Employees | 213 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 29.03% 4.74% | SMA200 | 13.16% ($16.35) | Avg Volume(3M) | 0.30M | Price | $18.5 |
| IPO | 1997/6/18 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🧬 A pharmaceutical simulation software company that uses computer modeling to predict the absorption, distribution, metabolism, and excretion (ADME) of drugs during the drug development process. A leading company in the field of physiologically based pharmacokinetic (PBPK) modeling, its flagship product, GastroPlus, is deeply embedded in the regulatory review workflow for new drugs.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
SLP makes money exceptionally well
Of every $100 in sales, $14.63 is kept as operating profit.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $4,622. Peers typically go for $4,549. Compared with its own 4-year average, it is 42% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -53.4%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 88.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #23 of 42 in the industry
Based on market cap of $374M.
NRC#20 NRC Health $532M PER 86.6 
EVH#21 Evolent Health Inc $486M PER - 
CARL#22 Carlsmed Inc $393M PER - SLP#23 Simulations Plus Inc $374M PER 46.2 
CTEV#23 Claritev Corp $356M PER - 
FAQ
What kind of company is SLP?
SLP belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of SLP?
The market cap of SLP is approximately $374M, ranking 3,405 within its sector.
What is the P/E ratio of SLP?
SLP has a P/E ratio of approximately 46.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SLP?
SLP has recorded a 52-week high of $21.01 and a low of $11.09.
